Edition:
United Kingdom

Seattle Genetics Inc (SGEN.OQ)

SGEN.OQ on NASDAQ Stock Exchange Global Select Market

55.26USD
11 Dec 2017
Change (% chg)

-- (--)
Prev Close
$55.26
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
348,771
52-wk High
$71.31
52-wk Low
$45.31

Latest Key Developments (Source: Significant Developments)

TAKEDA RECEIVES POSITIVE CHMP OPINION FOR ADCETRIS FOR CD30-POSITIVE CUTANEOUS T-CELL LYMPHOMA
Tuesday, 14 Nov 2017 

Nov 14 (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T>::TAKEDA RECEIVES POSITIVE CHMP OPINION FOR ADCETRIS® (BRENTUXIMAB VEDOTIN) FOR CD30-POSITIVE CUTANEOUS T-CELL LYMPHOMA.‍CHMP POSITIVE OPINION FOR ADCETRIS WILL NOW BE REVIEWED BY EUROPEAN COMMISSION​.‍EMA COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE ADOPTED POSITIVE OPINION FOR EXTENSION OF MARKETING AUTHORIZATION OF ADCETRIS​.‍CHMP RECOMMENDED ADCETRIS​ ITS APPROVAL FOR TREATMENT OF ADULT PATIENTS WITH CD30-POSITIVE CUTANEOUS T-CELL LYMPHOMA.‍SEATTLE GENETICS AND TAKEDA ARE JOINTLY DEVELOPING ADCETRIS​.  Full Article

SEATTLE GENETICS ANNOUNCES FDA APPROVAL OF ADCETRIS (BRENTUXIMAB VEDOTIN)
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Seattle Genetics Inc ::SEATTLE GENETICS ANNOUNCES FDA APPROVAL OF ADCETRIS® (BRENTUXIMAB VEDOTIN) FOR PRIMARY CUTANEOUS ANAPLASTIC LARGE CELL LYMPHOMA (PCALCL) AND CD30-EXPRESSING MYCOSIS FUNGOIDES (MF).SEATTLE GENETICS INC - ‍FDA ALSO GRANTED PRIORITY REVIEW FOR SUPPLEMENTAL BIOLOGICS LICENSE APPLICATION FOR ADCETRIS​.SEATTLE GENETICS INC - ‍PRESCRIPTION DRUG USER FEE ACT TARGET ACTION DATE FOR ADCETRIS WAS DECEMBER 16, 2017​.  Full Article

Seattle Genetics, Astellas initiate phase 1b trial for Enfortumab Vedotin
Wednesday, 8 Nov 2017 

Nov 8 (Reuters) - Seattle Genetics Inc :Seattle Genetics and Astellas initiate phase 1B trial of Enfortumab Vedotin in combination with immune checkpoint inhibitor therapies in locally advanced or metastatic urothelial cancer.Primary objective of trial is to assess safety and tolerability of Enfortumab Vedotin in combination with CPI therapy​.  Full Article

Seattle Genetics submits supplemental license application for Adcetris
Thursday, 2 Nov 2017 

Nov 2 (Reuters) - Seattle Genetics Inc :Seattle genetics submits supplemental biologics license application to FDA for Adcetris (brentuximab vedotin) in frontline advanced hodgkin lymphoma.  Full Article

Seattle Genetics reports Q3 earnings $0.34/shr
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - Seattle Genetics Inc :Seattle Genetics reports third quarter 2017 financial results.Q3 earnings per share $0.34.Q3 revenue $135.3 million versus I/B/E/S view $112.8 million.Q3 earnings per share view $-0.42 -- Thomson Reuters I/B/E/S.Seattle Genetics Inc sees FY 2017 ‍revenues from collaboration and license agreements $90 million to $100 million​.Seattle Genetics Inc sees ‍fy 2017 royalty revenues $60 million to $65 million​.  Full Article

Seattle Genetics and Astellas initiate pivotal trial of enfortumab vedotin
Tuesday, 10 Oct 2017 

Oct 10 (Reuters) - Astellas Pharma Inc <4503.T>::Seattle Genetics and Astellas initiate pivotal trial of enfortumab vedotin for patients with locally advanced or metastatic urothelial cancer.Seattle Genetics Inc - ‍companies also plan to initiate a combination trial of enfortumab vedotin with CPI therapy in late 2017​.  Full Article

Genmab and Seattle Genetics to start Phase II study of tisotumab vedotin
Tuesday, 10 Oct 2017 

Oct 10 (Reuters) - Genmab A/S :Genmab and Seattle Genetics to initiate new study of novel antibody-drug conjugate tisotumab vedotin in cervical cancer.Genmab - ‍companies plan to start enrolling patients by first half of 2018​.Genmab - ‍co, Seattle Genetics to start phase II study of tisotumab vedotin in patients with recurrent and/or metastatic cervical cancer​.  Full Article

Seattle Genetics in licensing deal with Immunomedics
Friday, 10 Feb 2017 

Seattle Genetics Inc : Seattle Genetics announces global license agreement with immunomedics for sacituzumab govitecan (immu-132), a promising late-stage adc for solid tumors . Seattle Genetics Inc - planned bla for triple negative breast cancer indication; other solid tumors being explored in clinic . Seattle Genetics Inc - seattle genetics to lead development, manufacturing and commercialization of sacituzumab govitecan globally . Seattle Genetics inc says seattle genetics is purchasing approximately $15 million of common stock, representing a 2.8 percent stake in immunomedics . Seattle Genetics -upon closing of transactions contemplated by development, license agreement, immunomedics would receive an upfront payment of $250 million . Seattle Genetics Inc - granted right to purchase an additional 8,655,804 shares of common stock at a price of $4.90 per share . Seattle Genetics is purchasing approximately $15 million of common stock, representing a 2.8 percent stake in immunomedics . Seattle Genetics - would pay development, regulatory,sales-dependent milestone payments across multiple indications of up to total maximum of about $1.7 billion . Seattle Genetics Inc - 2017 guidance provided on february 9, does not take into account impact of transactions with immunomedics.  Full Article

Seattle Genetics-randomized phase 3 clinical trial with ADCETRIS meets primary endpoint
Monday, 1 Aug 2016 

Seattle Genetics Inc : Takeda and Seattle Genetics announce positive data from phase 3 Alcanza clinical trial of ADCETRIS® (Brentuximab Vedotin) for CD30-expressing cutaneous T-Cell Lymphoma . Randomized phase 3 clinical trial with ADCETRIS met primary endpoint . Intend to submit a supplemental biologics license application to FDA in first half of 2017 for approval .Phase 3 trial with ADCETRIS demonstrated highly statistically significant improvement in rate of objective response lasting at least 4 months.  Full Article

Seattle Genetics reports Q2 financial results
Tuesday, 26 Jul 2016 

Seattle Genetics Inc : Sees intiating phase 2 trial of denintuzumab mafodotin (SGN-CD19a; 19A) in frontline diffuse large B-cell lymphoma during 2016. . Seattle Genetics reports second quarter 2016 financial results . Q2 loss per share $0.23 . Q2 earnings per share view $-0.32 -- Thomson Reuters I/B/E/S .Q2 revenue $95.4 million versus I/B/E/S view $94.1 million.  Full Article

BRIEF-TAKEDA RECEIVES POSITIVE CHMP OPINION FOR ADCETRIS FOR CD30-POSITIVE CUTANEOUS T-CELL LYMPHOMA

* TAKEDA RECEIVES POSITIVE CHMP OPINION FOR ADCETRIS® (BRENTUXIMAB VEDOTIN) FOR CD30-POSITIVE CUTANEOUS T-CELL LYMPHOMA